SRNE logo

Sorrento Therapeutics (SRNE) Cash From Investing

Annual CFI

-$28.52 M
-$108.36 M-135.72%

December 31, 2022

Summary

Performance

1-Year Change

-135.72%

3-Year Change

+25.29%

5-Year Change

-72.53%

15-Year Change

-72.53%

SRNE Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

26.13%
SRNE annual cash flow from investing activities is higher than 26.13% of companies in Healthcare sector

High & Low

All-time High

$79.85 M
SRNE annual cash flow from investing activities is currently -135.72% below its historical high of $79.85 million

3-Year Low

-$28.52 M
SRNE annual cash flow from investing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
SRNE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
SRNE next annual earnings announcement has not yet been scheduled

OtherSRNEcash flowmetrics:

Annual CFF

$311.72 M
SRNE annual cash flow from financing activities is $311.72 million

Annual CFO

-$293.86 M
SRNE annual cash flow from operations is -$293.86 million

Annual FCF

-$307.51 M
SRNE annual free cash flow is -$307.51 million

Annual CAPEX

$13.66 M
SRNE annual capital expenditures is $13.66 million

Quarterly CFI

-$140.00 K
-$1.82 M-108.31%

June 30, 2023

Summary

Performance

3-Month Change

-108.31%

1-Year Change

-108.31%

3-Year Change

-108.31%

5-Year Change

-108.31%

SRNE Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

42.31%
SRNE quarterly cash flow from investing activities is higher than 42.31% of companies in Healthcare sector

High & Low

All-time High

$78.66 M
SRNE quarterly cash flow from investing activities is currently -100.18% below its historical high of $78.66 million

3-Year Low

-$13.66 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2023
SRNE previous earnings announcement was published on Jun 30, 2023

Next Quarterly Earnings Report Date

N/A
SRNE next earnings announcement has not yet been scheduled

OtherSRNEcash flowmetrics:

Quarterly CFF

$88.81 M
SRNE quarterly cash flow from financing activities is $88.81 million

Quarterly CFO

-$55.66 M
SRNE quarterly cash flow from operations is -$55.66 million

Quarterly FCF

-$55.80 M
SRNE quarterly free cash flow is -$55.80 million

Quarterly CAPEX

$140.00 K
SRNE quarterly capital expenditures is $140.00 thousand

TTM CFI

-$11.58 M
+$1.59 M+12.06%

June 30, 2023

Summary

Performance

3-Month Change

+12.06%

1-Year Change

+12.06%

3-Year Change

+12.06%

5-Year Change

+12.06%

SRNE TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

33.8%
SRNE TTM cash flow from investing activities is higher than 33.8% of companies in Healthcare sector

High & Low

All-time High

$79.85 M
SRNE TTM cash flow from investing activities is currently -114.51% below its historical high of $79.85 million

3-Year Low

-$28.52 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2023
SRNE previous earnings announcement was published on Jun 30, 2023

Next Quarterly Earnings Report Date

N/A
SRNE next earnings announcement has not yet been scheduled

OtherSRNEcash flowmetrics:

TTM CFF

$246.59 M
SRNE TTM cash flow from financing activities is $246.59 million

TTM CFO

-$234.63 M
SRNE TTM cash flow from operations is -$234.63 million

TTM FCF

-$243.21 M
SRNE TTM free cash flow is -$243.21 million

TTM CAPEX

$8.59 M
SRNE TTM capital expenditures is $8.59 million

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

SRNE Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-135.7%-108.3%+12.1%
3 y3 years+25.3%-108.3%+12.1%
5 y5 years-72.5%-108.3%+12.1%

SRNE Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-135.7%at low-108.3%+99.0%-114.5%+59.4%
5 y5-year-135.7%+28.6%-100.2%+99.5%-114.5%+72.4%
alltimeall time-135.7%+28.6%-100.2%+99.5%-114.5%+73.1%

Sorrento Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Jun 2023
-
-$140.00 K(-108.3%)
-$11.58 M(-12.1%)
Mar 2023
-
$1.68 M(-133.5%)
-$13.17 M(-53.8%)
Dec 2022
-$28.52 M(-135.7%)
-$5.03 M(-37.8%)
-$28.52 M(+11.0%)
Sep 2022
-
-$8.09 M(+368.3%)
-$25.69 M(+110.5%)
Jun 2022
-
-$1.73 M(-87.4%)
-$12.20 M(-117.9%)
Mar 2022
-
-$13.66 M(+519.7%)
$68.19 M(-14.6%)
Dec 2021
$79.85 M(-300.0%)
-$2.21 M(-140.9%)
$79.85 M(+13.0%)
Sep 2021
-
$5.40 M(-93.1%)
$70.64 M(+76.5%)
Jun 2021
-
$78.66 M(-4021.3%)
$40.02 M(-195.5%)
Mar 2021
-
-$2.01 M(-82.4%)
-$41.91 M(+5.0%)
Dec 2020
-$39.92 M(+4.6%)
-$11.41 M(-54.8%)
-$39.92 M(+2.6%)
Sep 2020
-
-$25.23 M(+673.6%)
-$38.90 M(+129.8%)
Jun 2020
-
-$3.26 M(>+9900.0%)
-$16.93 M(+6.3%)
Mar 2020
-
-$21.00 K(-99.8%)
-$15.93 M(-58.3%)
Dec 2019
-$38.17 M(+80.1%)
-$10.39 M(+219.1%)
-$38.17 M(+14.9%)
Sep 2019
-
-$3.26 M(+44.1%)
-$33.23 M(-22.6%)
Jun 2019
-
-$2.26 M(-89.9%)
-$42.91 M(-0.2%)
Mar 2019
-
-$22.27 M(+308.8%)
-$43.02 M(+102.9%)
Dec 2018
-$21.20 M(+28.2%)
-$5.45 M(-57.9%)
-$21.20 M(+22.2%)
Sep 2018
-
-$12.94 M(+447.2%)
-$17.35 M(+92.7%)
Jun 2018
-
-$2.36 M(+427.7%)
-$9.00 M(-29.8%)
Mar 2018
-
-$448.00 K(-72.0%)
-$12.82 M(-22.5%)
Dec 2017
-$16.53 M(-5.3%)
-$1.60 M(-65.1%)
-$16.53 M(-39.5%)
Sep 2017
-
-$4.59 M(-25.7%)
-$27.34 M(+7.0%)
Jun 2017
-
-$6.18 M(+48.5%)
-$25.56 M(+21.6%)
Mar 2017
-
-$4.16 M(-66.5%)
-$21.02 M(+20.4%)
Dec 2016
-$17.45 M(-239.0%)
-$12.41 M(+342.1%)
-$17.45 M(+156.8%)
Sep 2016
-
-$2.81 M(+71.8%)
-$6.79 M(-130.4%)
Jun 2016
-
-$1.63 M(+174.2%)
$22.32 M(+61.8%)
Mar 2016
-
-$596.00 K(-66.1%)
$13.80 M(+9.9%)
Dec 2015
$12.55 M(-218.5%)
-$1.76 M(-106.7%)
$12.55 M(+202.4%)
Sep 2015
-
$26.31 M(-359.0%)
$4.15 M(-118.5%)
Jun 2015
-
-$10.16 M(+451.1%)
-$22.39 M(+81.5%)
Mar 2015
-
-$1.84 M(-81.9%)
-$12.34 M(+16.5%)
Dec 2014
-$10.59 M
-$10.16 M(+4222.6%)
-$10.59 M(+5416.1%)
Sep 2014
-
-$235.00 K(+126.0%)
-$192.00 K(-59.4%)
Jun 2014
-
-$104.00 K(+10.6%)
-$473.00 K(+21.3%)
DateAnnualQuarterlyTTM
Mar 2014
-
-$94.00 K(-139.0%)
-$390.00 K(-22.5%)
Dec 2013
-$503.00 K(-8.2%)
$241.00 K(-146.7%)
-$503.00 K(-37.2%)
Sep 2013
-
-$516.00 K(+2357.1%)
-$800.90 K(+72.1%)
Jun 2013
-
-$21.00 K(-89.9%)
-$465.30 K(-12.1%)
Mar 2013
-
-$207.00 K(+263.8%)
-$529.50 K(-3.4%)
Dec 2012
-$548.00 K(-47.9%)
-$56.90 K(-68.5%)
-$548.00 K(-25.2%)
Sep 2012
-
-$180.40 K(+111.7%)
-$732.20 K(+19.4%)
Jun 2012
-
-$85.20 K(-62.2%)
-$613.30 K(-46.3%)
Mar 2012
-
-$225.50 K(-6.5%)
-$1.14 M(+8.5%)
Dec 2011
-$1.05 M(+2186.3%)
-$241.10 K(+292.0%)
-$1.05 M(+29.7%)
Sep 2011
-
-$61.50 K(-90.0%)
-$810.60 K(+8.2%)
Jun 2011
-
-$613.30 K(+351.6%)
-$749.10 K(+426.8%)
Mar 2011
-
-$135.80 K(<-9900.0%)
-$142.20 K(+209.1%)
Dec 2010
-$46.00 K(-177.6%)
$0.00(0.0%)
-$46.00 K(-20.0%)
Sep 2010
-
$0.00(-100.0%)
-$57.50 K(-532.3%)
Jun 2010
-
-$6400.00(-83.8%)
$13.30 K(-32.5%)
Mar 2010
-
-$39.60 K(+244.3%)
$19.70 K(-66.8%)
Dec 2009
$59.30 K(>+9900.0%)
-$11.50 K(-116.2%)
$59.30 K(-16.2%)
Sep 2009
-
$70.80 K(>+9900.0%)
$70.80 K(>+9900.0%)
Jun 2009
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2008
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2008
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2008
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2008
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2007
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2007
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2007
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2007
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2006
$0.00(0.0%)
-
-
Dec 2005
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2005
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2005
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2005
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2004
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2004
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2004
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2004
-
$0.00
$0.00
Dec 2003
$0.00
-
-

FAQ

  • What is Sorrento Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Sorrento Therapeutics?
  • What is Sorrento Therapeutics annual CFI year-on-year change?
  • What is Sorrento Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Sorrento Therapeutics?
  • What is Sorrento Therapeutics quarterly CFI year-on-year change?
  • What is Sorrento Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Sorrento Therapeutics?
  • What is Sorrento Therapeutics TTM CFI year-on-year change?

What is Sorrento Therapeutics annual cash flow from investing activities?

The current annual CFI of SRNE is -$28.52 M

What is the all time high annual CFI for Sorrento Therapeutics?

Sorrento Therapeutics all-time high annual cash flow from investing activities is $79.85 M

What is Sorrento Therapeutics annual CFI year-on-year change?

Over the past year, SRNE annual cash flow from investing activities has changed by -$108.36 M (-135.72%)

What is Sorrento Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of SRNE is -$140.00 K

What is the all time high quarterly CFI for Sorrento Therapeutics?

Sorrento Therapeutics all-time high quarterly cash flow from investing activities is $78.66 M

What is Sorrento Therapeutics quarterly CFI year-on-year change?

Over the past year, SRNE quarterly cash flow from investing activities has changed by -$1.82 M (-108.31%)

What is Sorrento Therapeutics TTM cash flow from investing activities?

The current TTM CFI of SRNE is -$11.58 M

What is the all time high TTM CFI for Sorrento Therapeutics?

Sorrento Therapeutics all-time high TTM cash flow from investing activities is $79.85 M

What is Sorrento Therapeutics TTM CFI year-on-year change?

Over the past year, SRNE TTM cash flow from investing activities has changed by +$1.59 M (+12.06%)